Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Hears Competing Messages On Off-Label Communications

Executive Summary

Over the course of a two-day meeting at FDA headquarters, the agency heard from the medtech industry, which argued for expanding rights to off-label promotion, and consumer groups that worry about the possible impact on the public health. The meeting is intended to inform FDA's comprehensive review of its regulations and policies governing firms' communications about unapproved uses of approved/cleared products.

You may also be interested in...



FDA Memo Reiterates Off-Label Enforcement Policy

Pre-Trump agency memo on manufacturer communications about unapproved uses says new court rulings and studies on off-label uses and adverse reactions support restrictions; whether agency’s new leadership has the same view remains to be seen.

FDA Cracks Open Door For More Manufacturer Communications

Two draft guidance documents would allow a broader range of communications with payers and others about information not included on device labeling, or concerning products without FDA approval.

FDA Off-Label Speech Guidance May Focus On Payers, Attorneys Say

Definitive guidance from FDA on off-label communications may be some time away and is likely to focus on physicians and payers before consumer-focused messaging, according to attorney from Arnall Golden Gregory.

Related Content

Topics

UsernamePublicRestriction

Register

MT104089

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel